ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology annual meeting in Orlando. The same agent has also been found to be active against anaplastic large T-cell lymphoma in a study presented at the ASH conference by a group from Seattle. eCancer Radio’s Haematology Editor George Canellos from the Dana-Farber Cancer Institue and Harvard University discusses the clinical promise of these findings for advancing further response rates and “permanent remissions” in Hodgkin’s Disease.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110106GeorgeCanellos283n96PODCASTLoRes.mp3]
